A Phase 1b Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Golimumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 11 Nov 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.
- 09 May 2019 Planned number of patients changed from 30 to 15.
- 04 Mar 2019 Planned End Date changed from 7 Jul 2021 to 21 Feb 2021.